Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuezhikang versus pravastatin for triglyceride lowering in type 2 diabetes with dyslipidemia
ChiCTR2100046704Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Xuezhikang and pravastatin in dyslipidemia and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Fasting blood lipid routine, Fasting hemoglobin A1c and 7 more. Started Jun 2021; status: recruiting.
02
Drugs
Xuezhikangpravastatin
03
Conditions
dyslipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100046704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046704.